Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.

@article{Keitel1999PhaseIT,
  title={Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.},
  author={Wendy A. Keitel and Kent E. Kester and Robert L. Atmar and A Cryptomathic White and Nichole Bond and Carolyn A. Holland and Urszula Krzych and Dupeh R Palmer and A Egan and Carter Diggs and William Ripley Ballou and B. Fenton Hall and David C Kaslow},
  journal={Vaccine},
  year={1999},
  volume={18 5-6},
  pages={531-9}
}
The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-1(19)) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-1(19) were well tolerated. Hypersensitivity reactions occurred in 3 subjects after… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…